Cyclobenzaprine Hydrochloride Tablet, Film Coated
Product Images NDC 85437-013

4 FDA label images from Carol Way Pharma Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 85437-013). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carol Way Pharma Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chart 1 (Chart 1)

Chart 1 (Chart 1)
A data table comparing the incidence of drowsiness, dry mouth, and dizziness between clinical studies and surveillance programs involving cyclobenzaprine hydrochloride 10 mg. The table shows percentages for each side effect in both study contexts.*
FDA Label Image

Chart A (Chart A)

Chart A (Chart A)
A data table comparing the incidence percentages of four side effects—drowsiness, dry mouth, fatigue, and headache—among three groups: Cyclobenzaprine Hydrochloride 5 mg (N=464), Cyclobenzaprine Hydrochloride 10 mg (N=249), and Placebo (N=469). The table presents higher rates of drowsiness and dry mouth in the Cyclobenzaprine groups compared to placebo.*
FDA Label Image

Label A (Label A)

Label A (Label A)
Label for Cyclobenzaprine Hydrochloride Tablets USP, 7.5 mg, film-coated oral tablets. The product is distributed by Carol Way Pharma LLC, San Antonio, TX, and manufactured in India. The label includes dosage and storage instructions, a warning to keep medication out of reach of children, and indicates the quantity of 1,000 tablets. The NDC is 85437-013-10.*
FDA Label Image

Image (Cyclobenzaprine HCl Tabs Structure)

Image (Cyclobenzaprine HCl Tabs Structure)
Chemical structure of cyclobenzaprine hydrochloride showing the three-ring core structure and the associated hydrochloride salt group. The image depicts the molecular framework characteristic to cyclobenzaprine, an active ingredient in the product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.